Oxford Biomedica (LON:OXB) Stock Passes Above 200-Day Moving Average - Should You Sell?

Key Points

• Oxford Biomedica's share price briefly rose above its 200-day moving average (200‑DMA GBX 664.76, intraday high GBX 666) but was last quoted at GBX 659 and is down about 1.5%.
• Street sentiment is largely positive—six Buys and one Hold yield a consensus "Moderate Buy" with an average target of GBX 687 and individual analyst targets up to GBX 950.
• The company shows weak fundamentals with negative earnings and margins (quarterly EPS GBX -26.92; forecast FY EPS -31.08) and a high debt-to-equity ratio of 116.74, highlighting ongoing profitability and leverage concerns.

Oxford Biomedica plc (LON:OXB - Get Free Report)'s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 664.76 and traded as high as GBX 666. Oxford Biomedica shares last traded at GBX 659, with a volume of 359,950 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on OXB shares. Jefferies Financial Group started coverage on Oxford Biomedica in a report on Monday, March 23rd. They issued a "buy" rating and a GBX 827 price objective on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a "buy" rating in a report on Friday, January 9th. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a GBX 950 price objective on shares of Oxford Biomedica in a report on Wednesday, March 11th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Oxford Biomedica presently has a consensus rating of "Moderate Buy" and an average target price of GBX 687.

Oxford Biomedica Stock Down 1.5%

The stock has a market capitalization of £784.76 million, a price-to-earnings ratio of -24.11 and a beta of 1.10. The business has a fifty day moving average of GBX 610.03 and a 200 day moving average of GBX 664.76. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67.

Oxford Biomedica (LON:OXB - Get Free Report) last released its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. As a group, equities analysts predict that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.